TrialLupus2018
A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
A Doria et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this paperpooled ittrialcites it